Annual EBITDA
-$565.47 M
-$168.03 M-42.28%
December 31, 2023
Summary
- As of February 7, 2025, BBIO annual EBITDA is -$565.47 million, with the most recent change of -$168.03 million (-42.28%) on December 31, 2023.
- During the last 3 years, BBIO annual EBITDA has fallen by -$98.09 million (-20.99%).
- BBIO annual EBITDA is now -1190.46% below its all-time high of -$43.82 million, reached on December 31, 2017.
Performance
BBIO EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$139.66 M
-$88.62 M-173.66%
September 30, 2024
Summary
- As of February 7, 2025, BBIO quarterly EBITDA is -$139.66 million, with the most recent change of -$88.62 million (-173.66%) on September 30, 2024.
- Over the past year, BBIO quarterly EBITDA has increased by +$8.82 million (+5.94%).
- BBIO quarterly EBITDA is now -823.53% below its all-time high of $19.30 million, reached on June 30, 2022.
Performance
BBIO Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$350.26 M
+$17.89 M+4.86%
September 30, 2024
Summary
- As of February 7, 2025, BBIO TTM EBITDA is -$350.26 million, with the most recent change of +$17.89 million (+4.86%) on September 30, 2024.
- Over the past year, BBIO TTM EBITDA has increased by +$215.21 million (+38.06%).
- BBIO TTM EBITDA is now -726.13% below its all-time high of -$42.40 million, reached on March 31, 2018.
Performance
BBIO TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
BBIO EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -42.3% | +5.9% | +38.1% |
| 3 y3 years | -21.0% | +5.9% | +38.1% |
| 5 y5 years | -238.8% | +5.9% | +38.1% |
BBIO EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -42.3% | at low | -823.5% | +22.0% | -3.2% | +38.1% |
| 5 y | 5-year | -102.7% | at low | -823.5% | +22.0% | -25.2% | +38.1% |
| alltime | all time | -1190.5% | at low | -823.5% | +22.0% | -726.1% | +38.1% |
BridgeBio Pharma EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$139.66 M(+173.7%) | -$350.26 M(-4.9%) |
| Jun 2024 | - | -$51.03 M(+360.0%) | -$368.14 M(-19.2%) |
| Mar 2024 | - | -$11.09 M(-92.5%) | -$455.58 M(-19.4%) |
| Dec 2023 | -$565.47 M(+42.3%) | -$148.47 M(-5.8%) | -$565.47 M(+5.5%) |
| Sep 2023 | - | -$157.54 M(+13.8%) | -$535.91 M(+7.8%) |
| Jun 2023 | - | -$138.47 M(+14.5%) | -$497.09 M(+46.5%) |
| Mar 2023 | - | -$120.98 M(+1.7%) | -$339.32 M(-14.6%) |
| Dec 2022 | -$397.44 M(-25.5%) | -$118.92 M(+0.2%) | -$397.44 M(-4.0%) |
| Sep 2022 | - | -$118.72 M(-715.1%) | -$414.14 M(-7.0%) |
| Jun 2022 | - | $19.30 M(-110.8%) | -$445.11 M(-19.4%) |
| Mar 2022 | - | -$179.10 M(+32.1%) | -$552.16 M(+3.4%) |
| Dec 2021 | -$533.83 M | -$135.62 M(-9.4%) | -$533.83 M(+2.3%) |
| Sep 2021 | - | -$149.68 M(+70.6%) | -$521.84 M(+6.2%) |
| Jun 2021 | - | -$87.75 M(-45.4%) | -$491.39 M(-6.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$160.78 M(+30.0%) | -$527.61 M(+13.1%) |
| Dec 2020 | -$467.38 M(+67.5%) | -$123.63 M(+3.7%) | -$466.36 M(+10.0%) |
| Sep 2020 | - | -$119.24 M(-3.8%) | -$423.85 M(+16.7%) |
| Jun 2020 | - | -$123.97 M(+24.5%) | -$363.16 M(+16.6%) |
| Mar 2020 | - | -$99.53 M(+22.7%) | -$311.59 M(+11.4%) |
| Dec 2019 | -$278.96 M(+67.1%) | -$81.11 M(+38.5%) | -$279.82 M(+13.4%) |
| Sep 2019 | - | -$58.55 M(-19.1%) | -$246.77 M(+7.7%) |
| Jun 2019 | - | -$72.39 M(+6.8%) | -$229.06 M(+19.2%) |
| Mar 2019 | - | -$67.77 M(+41.0%) | -$192.13 M(+15.2%) |
| Dec 2018 | -$166.90 M(+280.9%) | -$48.06 M(+17.7%) | -$166.76 M(+40.5%) |
| Sep 2018 | - | -$40.84 M(+15.2%) | -$118.70 M(+52.5%) |
| Jun 2018 | - | -$35.45 M(-16.4%) | -$77.85 M(+83.6%) |
| Mar 2018 | - | -$42.40 M | -$42.40 M |
| Dec 2017 | -$43.82 M | - | - |
FAQ
- What is BridgeBio Pharma annual EBITDA?
- What is the all time high annual EBITDA for BridgeBio Pharma?
- What is BridgeBio Pharma annual EBITDA year-on-year change?
- What is BridgeBio Pharma quarterly EBITDA?
- What is the all time high quarterly EBITDA for BridgeBio Pharma?
- What is BridgeBio Pharma quarterly EBITDA year-on-year change?
- What is BridgeBio Pharma TTM EBITDA?
- What is the all time high TTM EBITDA for BridgeBio Pharma?
- What is BridgeBio Pharma TTM EBITDA year-on-year change?
What is BridgeBio Pharma annual EBITDA?
The current annual EBITDA of BBIO is -$565.47 M
What is the all time high annual EBITDA for BridgeBio Pharma?
BridgeBio Pharma all-time high annual EBITDA is -$43.82 M
What is BridgeBio Pharma annual EBITDA year-on-year change?
Over the past year, BBIO annual EBITDA has changed by -$168.03 M (-42.28%)
What is BridgeBio Pharma quarterly EBITDA?
The current quarterly EBITDA of BBIO is -$139.66 M
What is the all time high quarterly EBITDA for BridgeBio Pharma?
BridgeBio Pharma all-time high quarterly EBITDA is $19.30 M
What is BridgeBio Pharma quarterly EBITDA year-on-year change?
Over the past year, BBIO quarterly EBITDA has changed by +$8.82 M (+5.94%)
What is BridgeBio Pharma TTM EBITDA?
The current TTM EBITDA of BBIO is -$350.26 M
What is the all time high TTM EBITDA for BridgeBio Pharma?
BridgeBio Pharma all-time high TTM EBITDA is -$42.40 M
What is BridgeBio Pharma TTM EBITDA year-on-year change?
Over the past year, BBIO TTM EBITDA has changed by +$215.21 M (+38.06%)